

Economy · GS - II

“How can India balance pharmaceutical innovation with affordable access to medicines while negotiating international trade agreements?”

EXAM YEAR

DAILY PRACTICE 23/10/2026

PAPER

GS - II

SUBJECT

Economy

MARKS

10

WORD LIMIT

~150 words

Answer Hint

Data Exclusivity, TRIPS Agreement, Generic Medicines, Public Health, Intellectual Property Rights, Pharmaceutical Innovation, Affordable Healthcare, India-US Trade Relations.

Model Answer

Introduction:

India's pharmaceutical policy must balance incentives for medical innovation with the public interest in affordable medicines.

Key Issues:

1. Data exclusivity: It may restrict generic manufacturers' reliance on originator clinical-trial data, potentially delaying generic entry.
2. Affordable healthcare: Generic competition can reduce medicine prices and improve access, particularly for low-income households.
3. Innovation incentives: Pharmaceutical companies argue that stronger data protection can encourage investment in research and development.
4. International obligations: India must honour its applicable international commitments while preserving legitimate public-health policy space.

-

Way Forward:

1. Ensure trade agreements do not unnecessarily delay access to affordable generics.
2. Strengthen domestic pharmaceutical research through public funding and industry-academia partnerships.
3. Use transparent, evidence-based negotiations and protect legitimate trade secrets.
4. Maintain effective quality regulation and explore appropriate safeguards under applicable law.

-

Conclusion:

India's approach should encourage innovation without creating avoidable barriers to affordable medicines, keeping public health central to trade policy.